#### TANDEM DIABETES CARE INC

Form 4

January 02, 2014

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

**OMB APPROVAL** 

response...

if no longer subject to Section 16. Form 4 or

Check this box

**SECURITIES** Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

See Instruction 1(b).

(Print or Type Responses)

may continue.

1. Name and Address of Reporting Person \* 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading CAHILL EDWARD L Issuer Symbol TANDEM DIABETES CARE INC (Check all applicable) [TNDM] (Last) (First) (Middle) 3. Date of Earliest Transaction \_X\_\_ Director 10% Owner Other (specify Officer (give title (Month/Day/Year) C/O HLM VENTURE 12/30/2013 PARTNERS,, 222 BERKELEY STREET (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check

Filed(Month/Day/Year) Applicable Line) \_X\_ Form filed by One Reporting Person

Form filed by More than One Reporting Person

BOSTON, MA 02116

(City)	(State) (	Zip) Table	e I - Non-D	erivative S	Securi	ties Acq	uired, Disposed o	f, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securit or(A) or Dis (Instr. 3, 4)	sposed	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	12/30/2013		X	85,096	A	\$ 7.37	1,739,154	I	Directly owned by HLM Venture Partners II,

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form

L.P. (1)

### Edgar Filing: TANDEM DIABETES CARE INC - Form 4

# displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Preferred Stock Warrant	\$ 7.37	12/30/2013		X	52,316	<u>(3)</u>	08/17/2021	Common Stock	52,316
Preferred Stock Warrant	\$ 7.37	12/30/2013		X	13,078	(3)	05/25/2022	Common Stock	13,078
Preferred Stock Warrant	\$ 7.37	12/30/2013		X	19,702	(3)	07/17/2022	Common Stock	19,702

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
1	Director	10% Owner	Officer	Other		
CAHILL EDWARD L C/O HLM VENTURE PARTNERS, 222 BERKELEY STREET BOSTON, MA 02116	X					

Reporting Owners 2

#### Edgar Filing: TANDEM DIABETES CARE INC - Form 4

## **Signatures**

/s/ David B. Berger, Attorney-in-Fact for Edward L. Cahill

01/02/2014

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The Reporting Person is a managing member of HLM Venture Associates II, L.L.C. ("Associates"), the general partner of HLM Venture Partners II, L.P. ("Partners"). As a managing member of Associates, the Reporting Person shares voting and investment power over the securities held by Partners and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Partners, except to the extent of his proportionate pecuniary interest therein.
- Upon consummation of the Issuer's initial public offering, these warrants automatically became exercisable for 52,316 shares of the (2) Issuer's common stock at an exercise price of \$7.37 per share, which reflects the effect of a 1-for-1.6756 reverse stock split that occurred in connection with the initial public offering.
- (3) The warrants are immediately exercisable.
  - Upon consummation of the Issuer's initial public offering, these warrants automatically became exercisable for 13,078 shares of the
- (4) Issuer's common stock at an exercise price of \$7.37 per share, which reflects the effect of a 1-for-1.6756 reverse stock split that occurred in connection with the initial public offering.
- Upon consummation of the Issuer's initial public offering, these warrants automatically became exercisable for 19,702 shares of the
- (5) Issuer's common stock at an exercise price of \$7.37 per share, which reflects the effect of a 1-for-1.6756 reverse stock split that occurred in connection with the initial public offering.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3